Đang chuẩn bị liên kết để tải về tài liệu:
Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: Mortality, clinical response and radiological characteristics

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG Tải xuống

Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The reported in-hospital mortality rates of ILD patients with ARF are high (62–66%). Cyclophosphamide is considered a second-line treatment in steroid-refractory ILD-associated ARF. |